← Eichor
Study identifier: NCT07565844 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Intradermal Exosomes, Platelet-Rich Plasma, and Steroids for Post-Herpetic Neuralgia

Condition: Postherpetic Neuralgia ( PHN )  ·  Sponsor: Zagazig University

PhaseNA
Planned participants45
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This randomized controlled clinical trial will evaluate and compare the efficacy and safety of intradermal injection of exosomes, platelet-rich plasma, and corticosteroid in patients with post-herpetic neuralgia. Forty-five adult patients with dermatomal pain persisting for at least 90 days after herpes zoster will be enrolled from outpatient clinics. Participants will be assigned to one of three groups: intradermal exosome injection, intradermal autologous platelet-rich plasma injection, or intradermal triamcinolone acetonide injection. Each group will receive four treatment sessions every two weeks. Outcomes will include pain severity, neuropathic pain characteristics, quality of life, patient satisfaction, and adverse effects, assessed at baseline, at the final session, and during follow-up visits at 3 and 6 months after the last session.

This description comes directly from the study's public registry record.

Talk to the study team

mona Elradi  ·  +201067070550  ·  monaelradi@medicine.zu.edu.eg

Always discuss trial participation with your own doctor first.

Locations (1)

Zagazig University HospitalsZagazig, Zagazig, EgyptRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07565844